Evidence map›Paper›PMID 26266827›Full record

ArticleAmerican journal of respiratory and critical care medicine2015

Role of B Cell-Activating Factor in Chronic Obstructive Pulmonary Disease.

Leen J M Seys, Fien M Verhamme, Anja Schinwald, Hamida Hammad, Danen Mootoosamy Cunoosamy, Claudie Bantsimba-Malanda, Alan Sabirsh, Eileen McCall, Liz Flavell, Ronald Herbst and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in American journal of respiratory and critical care medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 120 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Observational
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Unraveling the Immune Profile in Emphysema Using Single-Cell and Imaging Mass Spectrometry.American journal of respiratory and critical care medicine · 2024
    Article
  15. Article
  16. The persistent inflammation in COPD: is autoimmunity the core mechanism?European respiratory review : an official journal of the European Respiratory Society · 2024
    Review
  17. Review
  18. Article
  19. Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 4 countries.

Leen J M Seys1 Laboratory for Translational Research in Obstructive Pulmonary Diseases, Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
Fien M Verhamme1 Laboratory for Translational Research in Obstructive Pulmonary Diseases, Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
Anja Schinwald2 AstraZeneca Respiratory, Inflammation and Autoimmune iMed, Molndal, Sweden.
Hamida Hammad3 Laboratory of Immunoregulation and Mucosal Immunity, Department for Molecular Biomedical Research, VIB, Ghent, Belgium.
Danen Mootoosamy Cunoosamy2 AstraZeneca Respiratory, Inflammation and Autoimmune iMed, Molndal, Sweden.
Claudie Bantsimba-Malanda5 Department of Research, MedImmune, LLC, Gaithersburg, Maryland.
Alan Sabirsh6 AstraZeneca Cardiovascular and Metabolic Disease iMed, Molndal, Sweden; and.
Eileen McCall6 AstraZeneca Cardiovascular and Metabolic Disease iMed, Molndal, Sweden; and.
Liz Flavell7 AstraZeneca Discovery Sciences iMed, Alderley Park, United Kingdom.
Ronald Herbst5 Department of Research, MedImmune, LLC, Gaithersburg, Maryland.
Sharen Provoost1 Laboratory for Translational Research in Obstructive Pulmonary Diseases, Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
Bart N Lambrecht3 Laboratory of Immunoregulation and Mucosal Immunity, Department for Molecular Biomedical Research, VIB, Ghent, Belgium.
Guy F Joos1 Laboratory for Translational Research in Obstructive Pulmonary Diseases, Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
Guy G Brusselle1 Laboratory for Translational Research in Obstructive Pulmonary Diseases, Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
Ken R Bracke1 Laboratory for Translational Research in Obstructive Pulmonary Diseases, Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
Ghent University Hospital · BEAstraZeneca (Sweden) · SEAltimmune (United States) · USAstraZeneca (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleB cell-activating factor (BAFF) plays a major role in activation of B cells and in adaptive humoral immune responses. In chronic obstructive pulmonary disease (COPD), lymphoid follicles have been associated with disease severity, and overexpression of BAFF has been demonstrated within lymphoid follicles of patients with severe COPD.

objectivesTo investigate expression and localization of BAFF in the lungs of patients with COPD and to study the role of BAFF in COPD by antagonizing BAFF in a mouse model of chronic cigarette smoke (CS) exposure.

methodsWe quantified and localized BAFF expression in lungs of never-smokers, smokers without COPD, and patients with COPD and in lungs of air- or CS-exposed mice by reverse-transcriptase polymerase chain reaction, ELISA, immunohistochemistry, and confocal imaging. Next, to investigate the role of BAFF in COPD, we antagonized BAFF by prophylactic or therapeutic administration of a soluble fusion protein of the BAFF-receptor, BAFFR-Fc, in mice exposed to air or CS for 24 weeks and evaluated several hallmarks of COPD and polarization of lung macrophages. MEASUREMENTS AND MAIN

resultsBAFF expression was significantly increased in lungs of patients with COPD and CS-exposed mice. BAFF staining in lymphoid follicles was observed around B cells, CD4(+) cells, dendritic cells, follicular dendritic cells, and fibroblastic reticular cells. Prophylactic and therapeutic administration of BAFFR-Fc in mice reduced pulmonary B-cell numbers and prevented CS-induced formation of lymphoid follicles and increases in immunoglobulin levels. Interestingly, prophylactic BAFFR-Fc administration significantly attenuated pulmonary inflammation and destruction of alveolar walls. Moreover, antagonizing BAFF altered the phenotype of alveolar and interstitial macrophages.

conclusionsBAFF is significantly increased in lungs of patients with COPD and is present around both immune and stromal cells within lymphoid follicles. Antagonizing BAFF in CS-exposed mice attenuates pulmonary inflammation and alveolar destruction.

Indexed as

Adaptive ImmunityAgedAnimalsB-Cell Activating FactorB-LymphocytesEnzyme-Linked Immunosorbent AssayFemaleHumansImmunohistochemistryLungLymphoid TissueMacrophagesMaleMiceMice, Inbred C57BLMiddle AgedB-Cell Activating FactorSmokeTNFSF13B protein, humanB cell–activating factorB lymphocytesCOPDlymphoid follicles

Identifiers

PMID26266827
OpenAlexW2147715650

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.